Add office photos
Engaged Employer
Zydus Lifesciences
4.1
based on 6.4k Reviews
Video summary
Company Overview
Associated Companies
Company Locations
Working at Zydus Lifesciences
Company Summary
In 1995 we dedicated ourselves to the welfare of people and depicted our commitment with a heart-to-heart portrait. Today, with our evolved brand identity, this commitment emerges stronger than ever.
Overall Rating
4.1/5
based on 6.4k reviews
5% above
industry average
Highly rated for
Salary, Skill development, Company culture
Work Policy
Work from office
84% employees reported
Monday to Saturday
60% employees reported
Strict timing
56% employees reported
No travel
48% employees reported
View detailed work policy
Top Employees Benefits
Job/Soft skill training
358 employees reported
Office cab/shuttle
349 employees reported
Health insurance
326 employees reported
Cafeteria
128 employees reported
View all benefits
About Zydus Lifesciences
Founded in1952 (73 yrs old)
India Employee Count10k-50k
Global Employee Count10k-50k
India HeadquartersAhmedabad, India, India
Websitezyduslife.com
Primary Industry
Other Industries
View in video summary
Zydus Lifesciences Limited formerly knowns as Cadila Healthcare Limited, a leading Indian Pharmaceutical company is a fully integrated, global healthcare provider. With in-depth domain expertise in the field of healthcare, it has strong capabilities across the spectrum of the pharmaceutical value chain. From formulations to active pharmaceutical ingredients. Zydus has earned a reputation amongst Indian pharmaceutical companies for providing comprehensive and complete healthcare solutions. One of the salient features of Zydus is its rich history and lineage. The origin of the company dates all the way back to the 1950s. The company was founded in the year 1952 by Mr. Ramanbhai B. Patel (late), a first-generation entrepreneur and a doyen in the field of Indian Pharmaceuticals. In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover of Rs. 250 crores in 1995 the group witnessed significant financial growth and registered a turnover of over Rs. 15,000 crores in FY-21. Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe.
Mission: To unlock new possibilities in life-sciences through quality healthcare solutions that impact lives.
Vision: To be a global life-sciences company transforming lives through pathbreaking discoveries.
Report error
Zydus Lifesciences Ratings
based on 6.4k reviews
Overall Rating
4.1/5
How AmbitionBox ratings work?
5
3.3k
4
1.6k
3
721
2
285
1
482
Category Ratings
4.0
Salary
3.9
Skill development
3.8
Company culture
3.8
Job security
3.8
Work-life balance
3.8
Work satisfaction
3.7
Promotions
Zydus Lifesciences is rated 4.1 out of 5 stars on AmbitionBox, based on 6.4k company reviews. This rating reflects a generally positive employee experience, indicating satisfaction with the company’s work culture, benefits, and career growth opportunities. AmbitionBox gathers authentic employee reviews and ratings, making it a trusted platform for job seekers and employees in India.
Read more
Gender Based Ratings at Zydus Lifesciences
based on 5.8k reviews
4.0
Rated by 406 Women
Rated 4.0 for Job security and 3.8 for Skill development
4.0
Rated by 5.4k Men
Rated 4.0 for Salary and 3.9 for Skill development
Work Policy at Zydus Lifesciences
based on 766 reviews in last 6 months
Work from office
84%
Hybrid
12%
Permanent work from home
4%
Zydus Lifesciences Reviews
Top mentions in Zydus Lifesciences Reviews
+ 5 more
Compare Zydus Lifesciences with Similar Companies
Change Company | Change Company | Change Company | ||
|---|---|---|---|---|
Overall Rating | 4.1/5 based on 6.4k reviews | 4.0/5 based on 7.3k reviews | 4.1/5 based on 6.5k reviews | 4.1/5 based on 7.4k reviews |
Highly Rated for | Salary Skill development Work-life balance | Skill development Company culture Work-life balance | Skill development Company culture Work-life balance | Skill development Salary Work-life balance |
Critically Rated for | No critically rated category | Promotions | No critically rated category | No critically rated category |
Primary Work Policy | Work from office 84% employees reported | Work from office 73% employees reported | Work from office 83% employees reported | Work from office 73% employees reported |
Rating by Women Employees | 4.0 Good rated by 406 women | 3.9 Good rated by 829 women | 4.0 Good rated by 398 women | 4.0 Good rated by 748 women |
Rating by Men Employees | 4.0 Good rated by 5.4k men | 4.0 Good rated by 6.1k men | 4.1 Good rated by 5.8k men | 4.1 Good rated by 6.3k men |
Job security | 3.8 Good | 3.5 Good | 3.7 Good | 3.7 Good |
View more
Zydus Lifesciences Salaries
Zydus Lifesciences salaries have received with an average score of 4.0 out of 5 by 6.4k employees.
Deputy Manager
(951 salaries)
Unlock
₹7 L/yr - ₹20 L/yr
Officer
(828 salaries)
Unlock
₹1.2 L/yr - ₹6.2 L/yr
Technical Assistant
(322 salaries)
Unlock
₹1.8 L/yr - ₹8.5 L/yr
Area Business Manager
(220 salaries)
Unlock
₹4.8 L/yr - ₹12 L/yr
Production Officer
(205 salaries)
Unlock
₹1.2 L/yr - ₹5.4 L/yr
Research Associate
(200 salaries)
Unlock
₹1.6 L/yr - ₹10.3 L/yr
Senior Associate
(186 salaries)
Unlock
₹2.8 L/yr - ₹12.3 L/yr
Medical Representative
(172 salaries)
Unlock
₹2.1 L/yr - ₹6.5 L/yr
Therapy Manager
(169 salaries)
Unlock
₹3.3 L/yr - ₹10 L/yr
Executive Production
(160 salaries)
Unlock
₹3.1 L/yr - ₹8.6 L/yr
Zydus Lifesciences Interview Questions
A Plant Operator was asked 6mo agoQ. What size do you run in the capsule?
A Technical Assistant was asked 8mo agoQ. What is the full form of PLC?
A Deputy Manager was asked Q. How is the training management system being handled?
An Executive was asked 1mo agoQ. What is quality assurance?
An Apprentice Trainee was asked 10mo agoQ. Which parameters are used in tablet manufacturing?
Zydus Lifesciences Jobs
Popular Designations Zydus Lifesciences Hires for
Popular Skills Zydus Lifesciences Hires for
Current Openings
Zydus Lifesciences News
View all
Stock Market Live: GIFT Nifty Implies Lower Open; Cyient, Nazara Tech, Railtel Shares In Focus
- The GIFT Nifty is indicating a lower open with Cyient, Nazara Tech, and Railtel shares in focus.
- Key resistance and support levels for Nifty 50 are 25,200 and 25,000 respectively, as per Aditya Gaggar, director of Progressive Shares.
- US stock markets saw a halt in the rally as tech stocks weighed down the S&P 500. Nasdaq Composite ended lower while Dow Jones remained flat.
- A smaller-than-expected rise in US consumer inflation in May eased concerns about tariffs affecting prices.
- The Gift Nifty was down 0.08% at 25,195.00, while NSE Nifty 50 index had a 0.15% advance.
- Investors are monitoring Cyient Ltd., Nazara Tech, Railtel Corp of India, and Zydus Lifesciences Ltd.
- Benchmark equity indices closed higher on Wednesday after a slight decline on Tuesday.
- NSE Nifty 50 ended 0.15% higher at 25,141 and BSE Sensex closed 0.15% up at 82,515.
Bloomberg Quint | 12 Jun, 2025
Stock Recommendations Today: Torrent Pharma, Zydus, Hindalco On Brokerages' Radar
- Analyst calls on Torrent Pharma, Zydus, and Hindalco were featured in the recommendations today.
- Citi expects Torrent Pharma to sustain margin expansion driven by operating leverage in branded markets post a strong Q4 result.
- Citi also views Hindalco positively due to stronger aluminum performance and debt reduction but recommends a 'sell' on Zydus.
- Morgan Stanley and JPMorgan comment on India's strong fundamentals and foreign investor interest in the country.
- Concerns on Zydus' margin contraction and positive outlook for Hindalco's aluminum performance were highlighted by analysts.
- Foreign portfolio positioning in India is at its weakest since 2000, but views on India are showing signs of change.
- Citi maintains a 'Buy' on Torrent Pharma with a target price of Rs 4,000, while JPMorgan hikes target price for Hindalco to Rs 720.
- Goldman Sachs projects India to be among the top economies by 2050 and emphasizes the growth potential of emerging markets like India and Indonesia.
- Stock recommendations and target prices for United Spirits, Bharat Electronics, and Dixon Technologies were also discussed.
- Analysts provided insights on various sectors and companies like United Spirits, Bharat Electronics, and Dixon Technologies in the current market scenario.
- India's market is expected to be more stock pickers' driven rather than macro-driven, with preferences for sectors like financials, consumer discretionary, and industrials.
Bloomberg Quint | 21 May, 2025
Trump’s move to bring down US medicine prices could take some sheen off India’s drugs, say observers
- The US President is expected to announce a new policy to bring down drug prices in the US and implement a 'most favoured nation' policy.
- This move may impact Indian drugmakers who export generic drugs to the US market as it could lower prices of innovator drugs, affecting the competitiveness of generics.
- Large Indian pharmaceutical companies like Sun Pharma, Dr Reddy’s, Glenmark, Lupin, and Zydus could be affected by this policy change.
- Industry observers are also concerned about the impact on differential pricing strategies of multinational drugmakers in India and possible implications for trade deals with China.
HinduBusinessLine | 12 May, 2025
Stocks To Watch Today: L&T, Biocon, Titan, Kalyan Jewellers, Britannia, Union Bank
- Lupin, Mahindra & Mahindra Financial Services, Brigade Enterprises, Tata Motors, Infosys, Bharat Petroleum Corp, Oil & Natural Gas Corp, Gensol Engineering, Birla Corp, Zydus Lifesciences, Reliance Industries are some companies in focus.
- Recent developments include Tata Motors merging Tata Motors Finance, Infosys dissolving its Mexican subsidiary, and BPCL winning wind farm projects in Madhya Pradesh and Maharashtra.
- Stock highlights show L&T's strong Q4FY25 results with revenue, Ebitda, and net profit growth, while Union Bank of India reports a significant increase in net profit in Q4FY25.
- Biocon, Titan, Britannia, Kalyan Jewellers have showcased positive Q4FY25 results with revenue growth, improved margins, and increased net profits.
- Other companies like Aarti Industries, Zee Entertainment, Rain Industries, Fine Organics have also reported their Q4FY25 results reflecting revenue, Ebitda, and net profit changes.
- The article provides insights on key financial metrics, business developments, and market actions of various companies in the current trading cycle.
- Overall, the stocks to watch today include those of L&T, Biocon, Titan, Kalyan Jewellers, Britannia, and Union Bank, with a focus on their quarterly performance and market dynamics.
Bloomberg Quint | 9 May, 2025
Stocks To Buy Today: TVS Motor, Prestige Estate, Zydus Among Others
- TVS Motor, Prestige Estate, and Zydus Lifesciences are among the stocks recommended to buy.
- TVS Motor stock is recommended with a target price of Rs 2,850 and a stop loss at Rs 2,745.
- Container Corporation of India is suggested to buy with a target price of Rs 710 and a stop loss at Rs 677.
- Prestige Estates Projects has a 'buy' recommendation with a target price of Rs 1,350.
Bloomberg Quint | 29 Apr, 2025
Stocks To Watch Today: RIL, HCLTech, Force Motors, L&T Finance, Tejas Networks
- Stocks to watch today include RIL, HCLTech, Force Motors, L&T Finance, Tejas Networks, RBL Bank, Tata Technologies, and Poonawala Fincorp.
- Key updates include HCL Technologies acquiring KHY E4lectronics, GAIL signing an MoU with Container Corp., and Axis Bank announcing a change in management.
- Other highlights involve Aditya Birla Sun Life planning to raise funds, Apollo Tyres closing operations in the Netherlands, and Mahindra & Mahindra acquiring SML Isuzu.
- Additionally, Aurobindo Pharma's positive opinion on Dazublys®, Zydus Lifesciences' inspection by USFDA, and Biocon's biosimilar approval by EMA were noted.
- Companies like Harsha Engineers, Alembic Pharma, and Eicher Motors introduced new facilities and products, while Railtel Corp received an order from The Institute of Road Transport.
- Post-market earnings highlighted performance by RBL Bank, Reliance Jio, Reliance Industries, Tata Technologies, DCB Bank, Poonawala Fincorp, Rossari Biotech, Oracle Financial Services, and others.
- Notable financial results included Force Motors' revenue and profit growth, LT Finance's increase in revenue and net profit, and Tejas Networks' decline in EBITDA and net profit.
- Further details on companies like Zensar Tech, Lloyds Metals and Energy, IDFC First Bank, MRPL, India Cements, Ugro Capital, SBFC Finance, IGL, and others were also provided.
- Earnings announcements to watch included UltraTech Cement, Aditya Birla Sun Life AMC, Castrol India, CSB Bank, Firstsource Solutions, Go Digit General Insurance, and more.
- The article covers various company updates, financial performances, and upcoming earnings reports to watch in the current market scenario.
- For more detailed information, readers can refer to the original article on NDTV Profit.
Bloomberg Quint | 28 Apr, 2025
Heard On The Street: Dealers Spot Action In IIFL Finance, Zydus Life, Lupin And Select IT Stocks
- IIFL Finance witnessed strong domestic institutional buying.
- Zydus Life and Lupin received positional buy calls in multiple dealing rooms.
- IT stocks like Tech Mahindra and Coforge attracted investor focus.
- Delivery-based buying continued in select IT names.
Bloomberg Quint | 22 Apr, 2025
Stocks To Watch Today: Infosys, HDFC Bank, ICICI Bank, Adani Ports, GAIL, Kolte-Patil Developers
- Stocks to watch today include Infosys, HDFC Bank, ICICI Bank, Adani Ports, GAIL, and Kolte-Patil Developers.
- Other stocks in focus before trading are Divi’s Laboratories, Zydus Lifesciences, and Tata Consultancy Services.
- Adani Ports announced acquisitions in Australia to boost cargo capacity significantly by 2030.
- Kolte-Patil Developers reported impressive fiscal 2025 sales and growth in project launches and collections.
- Zydus Lifesciences and Divi's Laboratories entered strategic agreements for technology commercialization and capacity expansion.
- GAIL faces a review of its integrated network tariff by the Petroleum and Natural Gas Regulatory Board.
- HDFC Bank and ICICI Bank posted their Q4FY25 earnings with positive growth in net profit and NPA figures.
- Yes Bank, HDFC Life Insurance, Infosys, Tata Elxsi, and other companies shared their financial results for Q4FY25.
- Earnings of companies like Mastek Ltd., Just Dial, Jio Financial Services, and more were also highlighted.
- Various developments, appointments, acquisitions, and financial outcomes across different sectors were reported for the day.
Bloomberg Quint | 21 Apr, 2025
Zydus, Lupin Shares: Systematix Retains Hold, Cuts Target Price Over US Court Ruling In Myrbetriq Patent Case
- The US Court ruling in the Myrbetriq patent case has led Systematix to retain a hold rating on shares of Zydus and Lupin.
- Systematix has also cut the target price due to the court ruling which blocks the sale of generic versions of Myrbetriq in the US until the patent expires in March 2030.
- Lupin and Zydus Life had filed ANDAs with the USFDA to market generic versions of Myrbetriq, but their plans have been halted by the court ruling.
- The patent challenge made by Lupin and Zydus Life was rejected by the US District Court for the District of Delaware.
Bloomberg Quint | 17 Apr, 2025
Stock Recommendations Today: Wipro, Adani Ports, Angel One, Bharti Airtel, IndiGo On Brokerages' Radar
- Wipro Ltd. faced negative brokerage commentary after issuing weaker-than-expected revenue guidance and highlighting client uncertainty due to global tariff concerns.
- Brokerages like Citi, BofA Securities, and Investec trimmed price targets and earnings estimates for Wipro, anticipating another challenging year for the tech major.
- Morgan Stanley adjusted targets for consumer discretionary names, supporting disruptors like Trent Ltd. and raising price targets for Interglobe Aviation Ltd. in the travel sector.
- Analysts shared their recommendations on various stocks, with Citi retaining a 'sell' rating on Wipro and BofA Securities expecting a growth catch-up in the future.
- Morgan Stanley analyzed companies like Vedant Fashions, Aditya Birla Fashion, Trent, and Brainbees Solutions within the consumer discretionary segment, favoring businesses with strong competitive advantages.
- Adani Ports received positive feedback from Morgan Stanley for its resilient business model and strategy to reduce Ebitda sensitivity to cargo volumes.
- Angel One was recommended as a 'buy' by Investec, with noted earnings growth weaknesses in the upcoming fiscal year.
- HSBC raised the price target on InterGlobe Aviation and noted strong trading trends in the travel and hospitality sector.
- Bharti Airtel was highlighted by Bernstein as a top pick in the telecom sector, supported by strong defensive attributes and ongoing deleveraging.
- UBS shared insights on the Mirabegron litigation outcome, indicating potential challenges for Zydus and Lupin in the pharmaceutical space.
Bloomberg Quint | 17 Apr, 2025
Powered by
Zydus Lifesciences Subsidiaries
Zydus Healthcare
4.0
• 687 reviews
Zydus Hospital
4.3
• 262 reviews
German Remedies
4.0
• 91 reviews
Zydus Animal Health
3.6
• 63 reviews
Liva Pharmaceuticals
3.6
• 39 reviews
Zydus Pharmaceuticals
4.6
• 15 reviews
Report error
Compare Zydus Lifesciences with
Sun Pharmaceutical Industries
4.0
Aurobindo Pharma
4.0
Intas Pharmaceuticals
4.1
Hetero
3.8
Macleods Pharmaceuticals
3.6
Viatris
4.2
Alembic Pharmaceuticals
4.0
Abbott
4.1
Ipca Laboratories
3.9
Glenmark Pharmaceuticals
3.9
Alkem Laboratories
3.9
Mankind Pharma
3.9
Torrent Pharmaceuticals
3.9
MSN Laboratories
3.7
Ajanta Pharma
4.0
Akums Drugs & Pharmaceuticals Limited
4.4
GlaxoSmithKline Pharmaceuticals
4.1
Pfizer
3.9
DIVI'S Laboratories
3.7
Wockhardt
3.8
Contribute & help others!
You can choose to be anonymous
Companies Similar to Zydus Lifesciences
Cipla
Manufacturing, Pharma
4.1
• 7.4k reviews
Dr. Reddy's
Clinical Research, Pharma
4.0
• 7.3k reviews
Lupin
Biotech & Life sciences, Manufacturing, Pharma
4.1
• 6.5k reviews
Sun Pharmaceutical Industries
Healthcare / Pharma, Manufacturing, Analytics & KPO, Pharma
4.0
• 6.3k reviews
Aurobindo Pharma
Healthcare / Pharma, Biotechnology, Pharma
4.0
• 5.1k reviews
Intas Pharmaceuticals
Biotech & Life sciences, Pharma
4.1
• 3.8k reviews
Hetero
Healthcare / Pharma, Clinical Research, Healthcare, Pharma
3.8
• 3.6k reviews
Macleods Pharmaceuticals
Biotech & Life sciences, Pharma
3.6
• 3.6k reviews
Viatris
Manufacturing, Pharma
4.2
• 3.4k reviews
Alembic Pharmaceuticals
Real Estate, Engineering & Construction, Biotechnology, Pharma
4.0
• 3.3k reviews
Abbott
Healthcare / Pharma, Media & Entertainment / Publishing, Pharma
4.1
• 3.2k reviews
Ipca Laboratories
Pharma
3.9
• 3.1k reviews
Zydus Lifesciences FAQs
When was Zydus Lifesciences founded?
Zydus Lifesciences was founded in 1952. The company has been operating for 73 years primarily in the Pharma sector.
Where is the Zydus Lifesciences headquarters located?
Zydus Lifesciences is headquartered in Ahmedabad, India. It operates in 2 cities such as Ahmedabad, Mumbai. To explore all the office locations, visit Zydus Lifesciences locations.
How many employees does Zydus Lifesciences have in India?
Zydus Lifesciences currently has more than 26,000+ employees in India. Production, Manufacturing & Engineering department appears to have the highest employee count in Zydus Lifesciences based on the number of reviews submitted on AmbitionBox.
Does Zydus Lifesciences have good work-life balance?
Zydus Lifesciences has a Work-Life Balance Rating of 3.8 out of 5 based on 6,400+ employee reviews on AmbitionBox. 77% employees rated Zydus Lifesciences 4 or above, while 23% employees rated it 3 or below on work-life balance. This indicates that the majority of employees feel a generally balanced work-life experience, with some opportunities for improvement based on the feedback. We encourage you to read Zydus Lifesciences work-life balance reviews for more details.
Is Zydus Lifesciences good for career growth?
Career growth at Zydus Lifesciences is rated fairly well, with a promotions and appraisal rating of 3.7. 77% employees rated Zydus Lifesciences 4 or above, while 23% employees rated it 3 or below on promotions / appraisal. Though the sentiment is mixed for career growth, majority employees have rated it positively. We recommend reading Zydus Lifesciences promotions / appraisals reviews for more detailed insights.
What are the pros and cons of working in Zydus Lifesciences?
Working at Zydus Lifesciences comes with several advantages and disadvantages. It is highly rated for salary & benefits, skill development and company culture. However, it is poorly rated for promotions / appraisal, based on 6,400+ employee reviews on AmbitionBox.
Stay ahead in your career. Get AmbitionBox app
Trusted by over 1.5 Crore job seekers to find their right fit company
80 Lakh+
Reviews
10L+
Interviews
4 Crore+
Salaries
1.5 Cr+
Users
Contribute to help millions
AmbitionBox Awards
Get AmbitionBox app
Made with ❤️ in India. Trademarks belong to their respective owners. All rights reserved © 2025 Info Edge (India) Ltd.
Follow Us
